Nizatidine is an H2 receptor antagonist used to treat GERD and a variety of ulcers. A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion.
- Mechanism
- Curator reviewed
Nizatidine competes with histamine for binding at the H2-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin.
- Primary indication
- For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.Curator reviewed · 8 structured indications
- Formula / weight
- C12H21N5O2S2 · 331.45 g/mol (avg)
- First approval
- Canada, 1995 · United States, 1996
- Code names
- LY-139037
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
SGXXNSQHWDMGGP-UHFFFAOYSA-NSMILESCNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=OTargets
Transporters
What you can answer from here — as of September 12, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Nizatidine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account